60 results about "Epidermoid carcinoma" patented technology

Disclosed a saucernetin structurally simplified substance and the preparation method and pharmaceutical composition and use thereof. In particular, it relates to a compound of general formula (I) shown as formula (I) or an isomer thereof and a salt thereof, and the preparation method for such compounds. A novel pharmaceutical composition contains an effective amount of compound of formula I and a pharmacodynamically acceptable vector. The present invention also discloses the use of such compounds in preparing drugs for preventing and / or treating tumours. The tumours include neural glioblastoma, melanoma, gastric cancer, lung cancer, breast cancer, kidney cancer, liver cancer, oral epidermoid carcinoma, cervical cancer, ovarian cancer, pancreatic cancer, prostate cancer, and colon cancer and rectal adenocarcinoma.

The invention discloses application of a thiourea molecule in preparation of antitumor drugs. The structural formula of the thiourea molecule is selected from formula I to formula IV, wherein R1, R2 and R3 are independently selected from hydrogen, alkyl with a carbon number of 1-10, aryl or a heteroatom group containing N, O and S. The invention provides new application of the thiourea molecule, specifically in preparation of anticancer drugs. The thiourea molecule is adopted as the anti-cancer drug, or is used as the active ingredient for preparation of pharmaceutical preparations, the antitumor drugs show very low cytotoxicity to human lung adenocarcinoma cells (A549), human breast cancer cells (BCap-37), human oral epidermoid carcinoma cells (KB), human lung fibroblast (HFL1) and human bronchial epithelial cells (BEAS-2B), but has very good antitumor effect at the animal level. (formula I, formula II, formula III, and formula IV).

The invention discloses an application of an EGFR inhibitor in the preparation of a drug for the treatment of MUC1-positive tumors, and relates to the application of an inhibitor targeting the MUC1-EGFR-ABCB1 signaling pathway in combination with an ABCB1 substrate chemotherapeutic drug in the preparation of a drug for the treatment of MUC1-positive tumors. The present invention discloses the molecular mechanism by which chemotherapeutic drugs induce MUC1 expression and activate the MUC1-EGFR-ABCB1 signaling pathway in cervical cancer and lung mucoepidermoid cancer, and finally cause cells to pump the drugs out of the membrane to produce drug resistance. At the same time, targeted inhibition of EGFR can effectively inhibit the proliferation of cervical cancer and lung mucoepidermoid cancer cells, control the growth of transplanted tumors, and effectively prevent the recurrence of transplanted tumors. It is suggested that the combination of inhibitors targeting MUC1-EGFR-ABCB1 signaling pathway and ABCB1 substrate chemotherapeutic drugs has broad prospects in the preparation of MUC1-positive tumor drugs.